cisplatin + iodine-125

Cisplatin + iodine-125 is a combination therapy investigated for the treatment of malignant gliomas, including glioblastoma multiforme and anaplastic astrocytoma. This treatment approach utilizes **cisplatin**, a platinum-based chemotherapeutic agent, as a radiosensitizer to enhance the cytotoxic effects of radiation. **Iodine-125** is a radioactive isotope administered via interstitial brachytherapy, where radioactive seeds or sources are implanted directly into the tumor site to deliver localized, high-dose ionizing radiation. The combination aims to maximize local tumor control by inducing lethal DNA damage through both chemical alkylation and radiation-induced double-strand breaks, while minimizing systemic toxicity. Clinical studies have evaluated this regimen in conjunction with hyperfractionated external beam irradiation (HEBI) to improve outcomes in patients with aggressive brain tumors.

Other names

125I + cisplatininterstitial iodine-125 and concomitant cisplatin